Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.

CONCLUSION: This extension study demonstrated the long-term safety and efficacy of weekly rIX-FP in pediatric patients. Additionally, it showed that adequate bleed protection can be achieved with 10- or 14-day rIX-FP regimens in selected pediatric patients while maintaining safety. PMID: 32185782 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32185782?dopt=Abstract

Source: Thrombosis and Haemostasis - March 16, 2020 Category: Hematology Authors: Kenet G, Chambost H, Male C, Halimeh S, Lambert T, Li Y, Seifert W, Santagostino E Tags: Thromb Haemost Source Type: research